Chi­na reg­u­la­tors of­fer VIP treat­ment for 48 over­seas drugs they're ready to hus­tle up with ac­cel­er­at­ed re­views

Chi­na wants nov­el drugs al­ready ap­proved over­seas to be avail­able in the coun­try faster. And in case some drug­mak­ers didn’t get the memo, it’s now come up with a di­rect ap­peal.

Eight months af­ter the Chi­nese drug ad­min­is­tra­tion rolled out its new pri­or­i­ty re­view path­way, its Cen­ter for Drug Eval­u­a­tion has un­veiled a list of 48 drugs (which you can see be­low) ap­proved in the US, EU or Japan that are ur­gent­ly need­ed in the clin­i­cal set­ting. As long as the com­pa­nies can pro­vide ev­i­dence that the drug works equal­ly well across races, they can im­me­di­ate­ly ap­ply for mar­ket­ing ap­proval with the da­ta they have and will be el­i­gi­ble for pri­or­i­ty re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER